218
S. Okusu et al. / Journal of Fluorine Chemistry 143 (2012) 216–219
Table 2
Enantioselective trifluoromethylation of azomethine imines 1a–h with Me3SiCF3 catalyzed by 3d in Solkane1 365mfc.
O
O
cat. 3d (10 mol%)
KOH (6.0 equiv)
HN
N
Me3SiCF3
(4.0 equiv)
N
N
Solkane®365mfc, -20 °C
Ar
CF3
Ar
H
1a− h
(S)-2a− h
Entry
1
R
Time (h)
Yield (%)
eea
1
2b
3b,c
4b
5b
6
7b
8b
9d
1a
1b
1c
1d
1e
1f
Ph
14
10
18
12
12
17
21
21
18
99
80
65
87
95
90
94
84
72
86
84
89
89
86
96
96
74
86e
3-MeOC6H4
4-MeOC6H4
3-MeC6H4
4-MeC6H4
4-iPrC6H4
4-tBuC6H4
4-FC6H4
Ph
1g
1h
1a
a
Determined by chiral HPLC.
b
c
Me3SiCF3 (6.0 equiv.) and KOH (10.0 equiv.) were used.
3f was used instead of 3d.
d
e
The reaction was performed at a slightly large scale and product 2a was isolated by filtration, distillation and recrystallization. Solkane1 365mfc was recovered in 72% yield.
Before recrystallization.
3. Conclusion
0.60 mmol, 6.0 equiv.) in Solkane1 365mfc (1.0 mL) Me3SiCF3
(59.1
L, 0.40 mmol, 4.0 equiv.) was added at À20 8C under a
m
In conclusion, Solkane1 365mfc was introduced as an environ-
mentally benign alternative solvent for the enantioselective trifluor-
omethylation reaction of imine equivalents, azomethine imines 1. The
trifluoromethylated adducts can be readily converted into pharma-
ceutically important trifluoromethylated amines [10]. High chemical
yields and enantioselectivities (up to 96% ee) were achieved by
employing previously unknown N-2-iodobenzylcinchoninium bro-
mide 3d as a chiral catalyst. The novel catalyst 3d has a very simple
structure and is readily synthesized in one step from commercially
available cinchonine and o-iodobenzyl bromide in high yield.
nitrogen atmosphere. After the reaction mixture was stirred at the
same temperature for 14 h, it was quenched with sat. NH4Cl aq. The
aqueous layer was extracted with CH2Cl2, and the combined organic
layers was washed with brine, dried over Na2SO4 and concentrated
under reduced pressure. The residue was purified by column
chromatography on silica gel (n-hexane/ethyl acetate = 1/1) to give
trifluoromethylated compounds (S) – 2a (27.2 mg, 99%, 86% ee) as a
white solid; 1H NMR (CDCl3, 200 MHz)
d 1.32 (s, 3H), 1.48 (s, 3H),
1.62, 1.77 (AB quartet, J = 16.1 Hz, 2H), 4.51 (q, J = 8.9 Hz, 1H), 7.35–
7.42 (m, 3H), 7.46–7.51 (m, 2H), 7.58 (brs, 1H); 13C NMR (CD3OD,
150.9 MHz)
J = 280.2 Hz), 130.6, 131.3, 133.2, 133.5, 180.2; 19F NMR (CDCl3,
188 MHz)
1694, 1497, 1455, 1360, 1275, 1242, 1167, 1124, 1088, 1033, 898,
846, 710, 658 cmÀ1; mp = 191–192 8C (CH2Cl2/hexane); MS (EI, m/z)
272 (M+), HRMS calcd. for C13H15F3N2O: 272.1136, Found:
272.1138; the ee of the product was determined by HPLC using
an OJ-H column (n-hexane/i-PrOH = 95/5, flow rate 0.5 mL/min,
d 25.0, 30.9, 44.9, 67.5 (q, J = 28.2 Hz), 67.6 127.7 (q,
4. Experimental
d
À70.7 (d, J = 9.2 Hz, 3F); IR (KBr) 3186, 3086, 2980, 2929,
4.1. Preparation of N-2-iodobenzylcinchoninium bromide 3d
A solution of cinchonine (200 mg, 0.68 mmol) and o-iodobenzyl
bromide (222 mg, 0.75 mmol, 1.1 equiv.) in THF (20 mL)/MeCN
(5 mL) was refluxed under a nitrogen atmosphere. After 12 h, the
reaction mixture was concentrated under reduced pressure and
recrystallized from CH2Cl2/diethyl ether to give 3d (330 mg, 82%)
l
= 254 nm,
tmaj = 16.7 min, tmin = 21.6 min).
as a solid with a bisque color; 1H NMR (CD3OD, 300 MHz)
d 1.07 (m,
Acknowledgments
1H), 1.89–1.96 (m, 4H), 2.47 (t, J = 11.7 Hz, 1H), 2.64 (q, J = 8.3 Hz,
1H), 3.27–3.34 (m, 1H), 3.48 (t, J = 11.3 Hz, 1H), 4.12–4.16 (m, 2H),
4.71–4.77 (m, 1H), 5.26–5.45 (m, 4H), 6.05 (ddd, J = 7.0, 10.4,
17.3 Hz, 1H), 6.69 (s, 1H), 7.29 (t, J = 7.5 Hz, 1H), 7.61 (t, J = 7.5 Hz,
1H), 7.84 (t, J = 3.8 Hz, 2H), 7.98 (d, J = 4.8 Hz, 2H), 8.14 (t, J = 9.0 Hz,
2H), 8.42 (d, J = 6.0 Hz, 1H), 8.96 (d, J = 4.5 Hz, 1H); 13C NMR
This study was financially supported in part by Grants-in-Aid
for Scientific Research (24105513, 22106515, Project No. 2304).
We thank Dr. Max Braun, Solvay Fluor GmbH for the generous gift
of Solkane1 365mfc. We thank Tosoh F-Tech Ltd. for the generous
gift of Me3SiCF3. We also thank the Asahi Glass Foundation for
financial support.
(CD3OD, 150.9 MHz)
d 22.3, 24.7, 28.2, 38.9, 57.2, 58.2, 67.1, 67.4,
69.2, 106.4, 117.8, 121.1, 124.5, 126.1, 129.3, 130.2, 131.2, 132.2,
133.4, 136.6, 137.6, 142.7, 147.4, 148.7, 151.0; IR (KBr) 3382, 3163,
3089, 2884, 1639, 1587, 1509, 1459, 1424, 1329, 1281, 1206, 1169,
1130, 1053, 998, 932, 858, 760, 630, 551 cmÀ1; mp = 230 8C
(decomposed) (CH2Cl2/Et2O); MS (ESI, m/z) 511 (M+-Br).
References
[1] (a) R. Filler, Y. Kobayashi, Biomedicinal Aspects of Fluorine Chemistry, Elsevier
Biomedical Press and Kodansya Ltd., Amsterdam, 1982;
(b) R. Filler, Y. Kobayashi, L.M. Yagupolskii, Organofluorine Compounds in Me-
dicinal Chemistry and Biomedical Applications, Elsevier, Amsterdam/New York,
1993;
4.2. Trifluoromethylation of azomethine imine 1a in Solkane1 365mfc
catalyzed by 3d
(c) J.T. Welch, S. Eswarakrishman, Fluorine in Bioorganic Chemistry, Wiley, New
York, 1991;
(d) P. Krisch, Modern Fluoroorganic Chemistry, Wiley-VCH, Weinheim, 2004;
(e) V.P. Kukhar, V.A. Soloshonok, Fluorine-containing Amino Acids. Synthesis and
Properties, Wiley, Chichester, 1995.
Toa stirredsolution ofazomethineimine 1a(20.2 mg, 0.1 mmol),
catalyst 3d (5.9 mg, 0.010 mmol, 10 mol%) and KOH (33.7 mg,